TJ286B - A method for treatment or prevention of obesity - Google Patents
A method for treatment or prevention of obesityInfo
- Publication number
- TJ286B TJ286B TJ96000313A TJ96000313A TJ286B TJ 286 B TJ286 B TJ 286B TJ 96000313 A TJ96000313 A TJ 96000313A TJ 96000313 A TJ96000313 A TJ 96000313A TJ 286 B TJ286 B TJ 286B
- Authority
- TJ
- Tajikistan
- Prior art keywords
- obesity
- growth hormone
- effective amount
- prevention
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96862392A | 1992-10-29 | 1992-10-29 | |
| PCT/US1993/010259 WO1994009813A1 (en) | 1992-10-29 | 1993-10-26 | Method for treatment or prevention of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TJ286B true TJ286B (en) | 2000-12-13 |
Family
ID=25514516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TJ96000313A TJ286B (en) | 1992-10-29 | 1993-10-26 | A method for treatment or prevention of obesity |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0669832B1 (el) |
| JP (1) | JPH08502969A (el) |
| AT (1) | ATE143267T1 (el) |
| AU (1) | AU675996B2 (el) |
| CA (1) | CA2145501C (el) |
| DE (1) | DE69305091T2 (el) |
| DK (1) | DK0669832T3 (el) |
| ES (1) | ES2095086T3 (el) |
| GR (1) | GR3022074T3 (el) |
| LV (1) | LV11987B (el) |
| MD (1) | MD1486G2 (el) |
| TJ (1) | TJ286B (el) |
| WO (1) | WO1994009813A1 (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| TW318226B (el) * | 1995-05-11 | 1997-10-21 | Sega Enterprises Kk | |
| US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| EP1117425A2 (en) * | 1998-10-02 | 2001-07-25 | Celtrix Pharmaceuticals, Inc. | Methods for the treatment of non-thyroid disorders |
| SE0000837D0 (sv) | 2000-03-13 | 2000-03-13 | Pharmacia & Upjohn Ab | New use |
| DE10035227A1 (de) * | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| US6946243B2 (en) | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| WO2005020898A2 (en) | 2003-08-21 | 2005-03-10 | Tercica, Inc. | Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| JP3051145B2 (ja) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
-
1993
- 1993-10-26 DE DE69305091T patent/DE69305091T2/de not_active Expired - Lifetime
- 1993-10-26 EP EP93925058A patent/EP0669832B1/en not_active Expired - Lifetime
- 1993-10-26 AU AU54512/94A patent/AU675996B2/en not_active Expired
- 1993-10-26 JP JP6511254A patent/JPH08502969A/ja active Pending
- 1993-10-26 AT AT93925058T patent/ATE143267T1/de active
- 1993-10-26 WO PCT/US1993/010259 patent/WO1994009813A1/en active IP Right Grant
- 1993-10-26 TJ TJ96000313A patent/TJ286B/xx unknown
- 1993-10-26 CA CA002145501A patent/CA2145501C/en not_active Expired - Lifetime
- 1993-10-26 ES ES93925058T patent/ES2095086T3/es not_active Expired - Lifetime
- 1993-10-26 DK DK93925058.5T patent/DK0669832T3/da active
- 1993-10-26 MD MD96-0245A patent/MD1486G2/ro unknown
-
1996
- 1996-12-18 GR GR960403519T patent/GR3022074T3/el unknown
-
1997
- 1997-09-25 LV LVP-97-182A patent/LV11987B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU675996B2 (en) | 1997-02-27 |
| AU5451294A (en) | 1994-05-24 |
| CA2145501A1 (en) | 1994-05-11 |
| GR3022074T3 (en) | 1997-03-31 |
| MD960245A (en) | 1997-12-31 |
| ES2095086T3 (es) | 1997-02-01 |
| LV11987B (en) | 1998-06-20 |
| EP0669832A1 (en) | 1995-09-06 |
| CA2145501C (en) | 2004-08-10 |
| EP0669832B1 (en) | 1996-09-25 |
| LV11987A (lv) | 1998-03-20 |
| ATE143267T1 (de) | 1996-10-15 |
| DK0669832T3 (da) | 1997-03-17 |
| DE69305091T2 (de) | 1997-03-13 |
| DE69305091D1 (de) | 1996-10-31 |
| MD1486F2 (en) | 2000-06-30 |
| WO1994009813A1 (en) | 1994-05-11 |
| JPH08502969A (ja) | 1996-04-02 |
| MD1486G2 (ro) | 2001-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0536226T3 (el) | ||
| AU7178287A (en) | Remote administration of hyaluronic acid to mammals | |
| CA2114014A1 (en) | Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine | |
| EP1077721B8 (en) | Prevention and treatment of hypergastrinemia | |
| TJ286B (en) | A method for treatment or prevention of obesity | |
| KR900003205A (ko) | 제약 화합물 | |
| KR920700227A (ko) | 초고활성 인체 인슐린 동족체 | |
| PL308539A1 (en) | Therpene compounds and their apllication in reducing arachidinic acid and inflammation mediators release | |
| Sassolas et al. | Nocturnal continuous infusion of growth hormone (GH)-releasing hormone results in a dose-dependent accentuation of episodic GH secretion in normal men | |
| GB1474424A (en) | Pharmaceutical composition for treating diabetic ketoacidosis | |
| EP0845007A2 (en) | Pharmaceutical composition containing inhibitors of interferon-gamma | |
| EP0317933A3 (en) | Treatment of fibromyalgia | |
| EP0486944A3 (en) | Method of inhibiting tumor growth using xanthocillin x dimethylether | |
| Ørskov et al. | Observations during a clinical trial of Sandostatin® in acromegalic patients | |
| AU6196496A (en) | Treatment of insulin requiring mammals | |
| Habib | Calcium and Hormone Therapy of Essential Hypertension | |
| MX9709958A (es) | Un metodo para reducir la cantidad de insulina exogena administrada a un paciente que tenga diabetes melitus dependiente de insulina. | |
| EP1839673A3 (en) | Prevention and treatment of hypergastrinemia | |
| AU4918900A (en) | Interferon-beta use in the treatment of ewing's family of tumors | |
| UA31148A (uk) | Спосіб лікування псоріазу | |
| UA35855A (uk) | Спосіб лікування пилового бронхіту |